Group A: Low risk (bio)chemicals/botanicals/minerals

Main outcomes
Group A: Low risk (bio)chemicals/botanicals /minerals

Main outcomes

Number of trials: can be reduced
Need of harmonization
Extrapolation possibilities
Use of data from other zones
Need of pre-pre-meeting submission
1. Acceptable effectiveness levels and types of label claims

The dossier has to tell the story of the product
Justify the need for the market
Significant effect compared to untreated
Qualitative and Quantitative approach
Communication between farmers and applicant
It is what the farmer accepts
Control vs Suppression
2. Dose justification

No risk for environment and human, why do we need to prove minimum effective dose?

Could be a limited data set (Minimum requirements of EPPO guideline)
Provide information on MoA and lab trials
Make a reasonable combination of minimum effective dose and efficacy trials
3. Data requirement: what is the minimal amount of information to do a meaningful efficacy evaluation?

Minimum requirements in EPPO guidelines

- GEP field trials are required
- Data from non-EU countries: basically YES, depending on circumstances
- Non-GEP trials (i.e. scientific publications): they are welcome but must be scientifically reliable
4. Extrapolation possibilities/ justification of extrapolation.

For low risk products extrapolation should be possible
To have more flexibility
5. Quality of dossiers/ role of applicant.

pre-pre-submission meeting could help
Write good summary
Be critical (be realistic) on your own data
No extra guidance is needed
6. Usefulness of Value assessment

Value assessment is useful.
7. other topics and issues that you would like to discuss

Workshop on LRs
Realistic examples (data requirements on LRs)
Rapid follow-up
Make a realistic time line on proposals generated during this workshop:

Make it happen & Yes you/we can!